Ronald E. Blaylock Elected to Pfizer’s Board of Directors

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. today announced the election of Ronald E. Blaylock to its
Board of Directors, effective immediately. Mr. Blaylock was also
appointed to the Corporate Governance and Science and Technology
Committees of Pfizer’s Board.

Mr. Blaylock, 57, is the Founder, Managing Partner of GenNx360 Capital
Partners, a private equity firm focused on investing in industrial and
business services companies in the U.S. middle market, since 2006. Prior
to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed
Blaylock & Company, an investment banking firm. He has also held senior
management positions at UBS, PaineWebber Group, and Citicorp.

Mr. Blaylock also serves as a Director of CarMax, Inc., Radio One, Inc.
and W.R. Berkley, Inc., as well as a Director of Syncreon U.S., a
for-profit private company. He is a member of the Board of Trustees of
Carnegie Hall, the Board of Overseers of New York University Stern
School of Business, and the Board of Trustees of Prep for Prep, a
not-for-profit organization. Mr. Blaylock was voted Capital Raiser of
the Year by Corporate Finance Magazine in 1999, and was named one of the
Most Powerful Blacks on Wall Street by Black Enterprise Magazine in
2005, and Man of the Year by Covenant House.

“We are pleased to welcome Ron Blaylock to Pfizer’s Board of Directors.
He brings business, financial and leadership expertise, which will be an
asset to Pfizer’s diverse Board and to our company,” stated Ian Read,
Pfizer’s Chairman and Chief Executive Officer. “The addition of Ron to
our Board helps ensure that Pfizer continues to benefit from a breadth
and variety of experience.”

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. For more information, please visit us at www.pfizer.com.
In addition, to learn more, follow us on Twitter at @Pfizer and
@Pfizer_News, LinkedIn, YouTube and like us on Facebook at
Facebook.com/Pfizer.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006654/en/